ClinicalTrials.gg
CompletedNCT02106195Updated Mar 23, 2022Results posted

A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris

A Phase 2 interventional study of Belumosudil in Psoriasis Vulgaris, sponsored by Kadmon Corporation, LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-03-23.

Sponsored by Kadmon Corporation, LLC (part of Sanofi) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.

Enrollment
626th of 673
8 · median 77
Started
2014
with 38 others
Phase 2
200 of 764
5 open now
Registered
304th of 764
by date

Among the 764 studies in Psoriasis with a site in United States, this one is the 626th largest by enrollment of the 673 interventional ones that give a count, is one of 39 that started in 2014, is one of 200 in phase 2, and was the 304th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 764 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

The primary objective is to assess the safety and tolerability of 200 mg of belumosudil administered orally once daily for 28 days.

Read the detailed description

This will be a Phase 2a, open-label, single-arm, safety and tolerability study of belumosudil given daily for treatment of psoriasis.

Eight subjects with moderately severe psoriasis who have failed at least 1 line of systemic therapy will be enrolled.

Treatment Period Eligible subjects who have failed at least 1 line of systemic therapy will be entered and treated for 4 weeks (28 days) with 200 mg of belumosudil given orally once daily (QD).

Subjects will undergo medical history evaluations, physical examinations, vital sign measurements, weight, adverse event assessments, concomitant medication assessments, and laboratory testing including but not limited to blood sample collection for hematology and chemistry, urinalysis, coagulation, lipid panel, electrocardiogram, pregnancy test for females of childbearing potential, testing with the Psoriasis Area and Severity Index (PASI) scale and Physician Global Assessment (PGA) scale, and pharmacokinetic sampling.

Follow-up Period:

Visit will occur 4 weeks after the last dose of study drug in the Treatment Period of the study. This visit must be done within ± 3 days of the scheduled visit. The same assessments will be performed as in the Treatment Period.

The duration of the study is 12 weeks: up to 4 weeks for screening, 4 weeks of treatment, and 4 weeks of follow-up.

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of moderately severe plaque psoriasis that has been stable for 6 months and has failed at least one and is a candidate for additional systemic therapy.
  • Had a PASI of ≥12
  • At least 10% of body surface area that is affected by plaque psoriasis.
  • Willing to avoid tanning devices or sun bathing.
  • Willing to forgo systemic and topical treatments for psoriasis during the course of the study.
  • Adequate bone marrow function
  • Negative urine pregnancy test (for women of )
  • Agree to use a highly effective method of (\< 1% per year failure rate) during the study and for 1 month after the termination of the study.
  • Willing to complete all study measurements and assessments in compliance with the protocol.

Exclusion criteria

Exclusion Criteria:

  • Non-plaque or drug-induced psoriasis
  • Currently using or therapy except for Class 5 or weaker topical corticosteroids to the face, groin, or scalp
  • Using any topical therapy except for the following:

    1. Class 5 or weaker steroids and phototherapy for 4 weeks prior to study entry
    2. Immunosuppressive therapies for 4 weeks prior to study entry
    3. Methotrexate, acitretin, or cyclosporine for 4 weeks prior to study entry
    4. Biologic therapies for 3 months prior to study entry.
  • Concomitant condition requiring treatment with moderate to high dose steroids in the 12 weeks prior to screening.
  • Viral, fungal, or bacterial skin infection.
  • Pregnant or lactating woman.
  • Currently participating in another study with an drug or within 28 days of study entry
  • History or other evidence of severe illness or any other conditions that would make the subject, in the opinion of the investigator, unsuitable for the study
  • History or presence of any of the following:

    1. Hepatic disease and or (ALT) or aspartate aminotransferase (AST) > 1.5 × the (ULN) at screening
    2. Renal disease and/or serum creatinine > 1.5xULN at screening
  • Has (f) intervals of > 450 msec at the screening or pre-dose
  • Subject is receiving any drugs known to prolong the QTc interval, including any anti-arrhythmic medications within 2 weeks prior to screening
  • Subject is receiving any drug that is a strong CYP enzyme inhibitor
  • Subject is receiving any concomitant systemic drug that is metabolized by CYP enzyme
  • Previous exposure to KD025 or known allergy/sensitivity to KD025 or any other ROCK-2 inhibitor.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Belumosudil 200 mg

    Belumosudil 200 mg (two 100 mg capsules) orally once daily for 28 days

    Drug: Belumosudil

Interventions

  • Also known as: Rezurock (brand name), KD025, SLx-2119

06

What researchers measure

Primary outcomes

  1. Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability

    To evaluate the safety and tolerability of 200 mg of belumosudil administered PO QD to subjects for treatment of psoriasis

    Time frame: Up to 12 weeks:Up to 4 weeks screening (depending on signed informed consent + 4 weeks treatment + 4 weeks follow-up

Secondary outcomes

  1. Efficacy: Change in Overall PASI (Psoriasis Area and Severity Index) From Baseline to Week 4 and Week 8

    The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. The measures are the changes in PASI score at Week 4 from baseline and Week 8 from baseline. Negative changes are favorable; positive changes are unfavorable.

    Time frame: 8 weeks: 4-week (28-day) treatment + 4-week (28-day) follow-up

  2. Efficacy: Physician Global Assessment (PGA) at Week 4 and Week 8

    PGA score after treatment with belumosudil 200 mg PO QD at 4 weeks (28 days treatment) and at 8 weeks (additional 4 weeks follow-up). Categories: 100% = clear; 75% to 99% clearing (Excellent) = marked improvement, nearly normal skin texture, some erythema may be present; 50% to 74% clear (Good) = moderate improvement, plaque has cleared to point of small scattered papules with normal intervening epidermis; 25% to 49% clearing (Fair) = slight improvement, decrease in scaling and softening of plaque; 0% to 24% clearing (Poor) = little or no change in scaling, erythema, or plaque elevation; Worse

    Time frame: 8 weeks: 4-week (28-day) treatment + 4-week (28-day) follow-up

  3. PK: Cmax and Cmin

    Pharmacokinetic measures: Cmax = maximum observed plasma concentration; Cmin = minimum observed plasma concentration over 1 dosing period; KD025 = Parent Drug KD025; M1 = Metabolite KD025 M1; KD025 M2 = Metabolite M2. Day 1 Cmax: 8 subjects each in KD025 and M2, and 6 subjects in M1. Day 28 Cmax: 4 subjects each in KD025 and M2, and 1 subject in M1. Day 1 Cmin: 8 subjects each in KD025 and M2, and 3 subjects in M1. Day 28 Cmin: 4 subjects each in KD025 and M2, and 1 subject in M1.

    Time frame: Measured at Baseline (Day 1) and Week 4 (28 days): predose (0), 1, 2, 4, 8, and 24 hours post-dose

  4. PK: AUC(0-24) and AUC(Inf)

    Pharmacokinetic measures: AUC(0-24) = area under concentration time-curve from pre-dose (time 0) to 24 hours post-dose; AUC(inf) = area under concentration time-curve extrapolated from Day 1 to infinity; KD025 = Parent Drug KD025; M1 = Metabolite KD025 M1; KD025 M2 = Metabolite M2.

    Time frame: Measured at Baseline (Day 1) and Week 4 (28 days): predose (0), 1, 2, 4, 8, and 24 hours post-dose

  5. PK: Tmax

    Pharmacokinetic measure: Tmax = time of maximum observed plasma concentration. Day 1 Tmax: 7 subjects each in KD025 and M2, and 5 subjects in M1. Day 28 Tmax: 4 subjects each in KD025 and M2, and 1 subject in M1.

    Time frame: Measured at Baseline (Day 1) and Week 4 (28 days): predose (0), 1, 2, 4, 8, and 24 hours post-dose

  6. PK: t(1/2)

    KD025 = Parent Drug KD025; KD025 M2 = Metabolite M2; t(1/2) = apparent terminal elimination half-life

    Time frame: Measured at Baseline (Day 1) and Week 4 (28 days): predose (0), 1, 2, 4, 8, and 24 hours post-dose

07

Results

Posted Sep 13, 2021

Participant flow

Open-label, Phase 2a, single-arm study of subjects with moderately severe plaque psoriasis who had been stable for 6 months and had failed at least 1 line of systemic therapy. Subjects were recruited at 1 site in the U.S.

Participant flow — Overall Study
MilestoneBelumosudil 200 mg PO QD
Started8
Completed5
Not completed3
Withdrew: Adverse event2
Withdrew: Protocol violation1

Outcome measures

PrimaryNumber of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability

To evaluate the safety and tolerability of 200 mg of belumosudil administered PO QD to subjects for treatment of psoriasis

Time frame:
Up to 12 weeks:Up to 4 weeks screening (depending on signed informed consent + 4 weeks treatment + 4 weeks follow-up
Reported as:
Count of participants · Participants
Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability
ParticipantsBelumosudil 200 mg PO QD
All AEs4
Related AEs1
Grade ≥3 AEs1
Grade ≥3 Related AEs0
Grade 4 AEs0
Deaths0
SAEs1
Related SAEs0
AEs leading to discontinuation2
SecondaryEfficacy: Change in Overall PASI (Psoriasis Area and Severity Index) From Baseline to Week 4 and Week 8

The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. The measures are the changes in PASI score at Week 4 from baseline and Week 8 from baseline. Negative changes are favorable; positive changes are unfavorable.

Time frame:
8 weeks: 4-week (28-day) treatment + 4-week (28-day) follow-up
Reported as:
Mean · Score on a scale
Efficacy: Change in Overall PASI (Psoriasis Area and Severity Index) From Baseline to Week 4 and Week 8
Score on a scaleBelumosudil 200 mg PO QD
Baseline (Day 1)17.5 ± 8.41
Week 4 (Day 28)16.3 ± 9.49
Change from Baseline to Week 4-1.1 ± 3.04
Week 8 (Day 56)14.7 ± 3.41
Change from Baseline to Week 80.0 ± 1.54
Statistical analysis
  • Belumosudil 200 mg PO QD · t-test, 2 sided · p = 0.324 · Mean difference (final values): -1.1 · 95% CI -3.7 to 1.4
SecondaryEfficacy: Physician Global Assessment (PGA) at Week 4 and Week 8

PGA score after treatment with belumosudil 200 mg PO QD at 4 weeks (28 days treatment) and at 8 weeks (additional 4 weeks follow-up). Categories: 100% = clear; 75% to 99% clearing (Excellent) = marked improvement, nearly normal skin texture, some erythema may be present; 50% to 74% clear (Good) = moderate improvement, plaque has cleared to point of small scattered papules with normal intervening epidermis; 25% to 49% clearing (Fair) = slight improvement, decrease in scaling and softening of plaque; 0% to 24% clearing (Poor) = little or no change in scaling, erythema, or plaque elevation; Worse

Time frame:
8 weeks: 4-week (28-day) treatment + 4-week (28-day) follow-up
Reported as:
Count of participants · Participants
Efficacy: Physician Global Assessment (PGA) at Week 4 and Week 8
ParticipantsBelumosudil 200 mg PO QD
4 weeks: 75% to 100%0
4 weeks: 50% to 74% clearing1
4 weeks: 25% to 49% clearing1
4 weeks: 0 to 24% clearing4
4 weeks: Worse2
8 weeks: 75% to 100%0
8 weeks: 50% to 74% clearing0
8 weeks: 25% to 49% clearing0
8 weeks: 0% to 24% clearing6
8 weeks: Worse1
8 weeks: Missing (no data)1
SecondaryPK: Cmax and Cmin

Pharmacokinetic measures: Cmax = maximum observed plasma concentration; Cmin = minimum observed plasma concentration over 1 dosing period; KD025 = Parent Drug KD025; M1 = Metabolite KD025 M1; KD025 M2 = Metabolite M2. Day 1 Cmax: 8 subjects each in KD025 and M2, and 6 subjects in M1. Day 28 Cmax: 4 subjects each in KD025 and M2, and 1 subject in M1. Day 1 Cmin: 8 subjects each in KD025 and M2, and 3 subjects in M1. Day 28 Cmin: 4 subjects each in KD025 and M2, and 1 subject in M1.

Time frame:
Measured at Baseline (Day 1) and Week 4 (28 days): predose (0), 1, 2, 4, 8, and 24 hours post-dose
Reported as:
Mean · ng/mL
PK: Cmax and Cmin
ng/mLParent Drug KD025Metabolite M1Metabolite M2
Cmax: Day 11240 ± 70421.3 ± 10.9221 ± 165
Cmax: Day 28810 ± 47515.0 ± NA131 ± 152
Cmin: Day 159.6 ± 29.318.7 ± 9.1621.1 ± 6.13
Cmin: Day 2835.9 ± 22.910.7 ± NA17.6 ± 7.36
SecondaryPK: AUC(0-24) and AUC(Inf)

Pharmacokinetic measures: AUC(0-24) = area under concentration time-curve from pre-dose (time 0) to 24 hours post-dose; AUC(inf) = area under concentration time-curve extrapolated from Day 1 to infinity; KD025 = Parent Drug KD025; M1 = Metabolite KD025 M1; KD025 M2 = Metabolite M2.

Time frame:
Measured at Baseline (Day 1) and Week 4 (28 days): predose (0), 1, 2, 4, 8, and 24 hours post-dose
Reported as:
Mean · ng*hr/mL
PK: AUC(0-24) and AUC(Inf)
ng*hr/mLParent Drug KD025Metabolite M2
AUC(0-24): Day 17360 ± 31801040 ± 545
AUC(0-24): Day 285500 ± 3790162 ± 2320
AUC(inf) from Day 18230 ± 36001120 ± 680
SecondaryPK: Tmax

Pharmacokinetic measure: Tmax = time of maximum observed plasma concentration. Day 1 Tmax: 7 subjects each in KD025 and M2, and 5 subjects in M1. Day 28 Tmax: 4 subjects each in KD025 and M2, and 1 subject in M1.

Time frame:
Measured at Baseline (Day 1) and Week 4 (28 days): predose (0), 1, 2, 4, 8, and 24 hours post-dose
Reported as:
Median · hours
PK: Tmax
hoursParent Drug KD025Metabolite M1Metabolite M2
Tmax: Day 12.00 (1.00 to 7.92)2.00 (1.00 to 2.00)2.00 (1.00 to 7.92)
Tmax: Day 284.00 (1.00 to 4.13)4.00 (4.00 to 4.00)4.00 (1.00 to 4.13)
SecondaryPK: t(1/2)

KD025 = Parent Drug KD025; KD025 M2 = Metabolite M2; t(1/2) = apparent terminal elimination half-life

Time frame:
Measured at Baseline (Day 1) and Week 4 (28 days): predose (0), 1, 2, 4, 8, and 24 hours post-dose
Reported as:
Mean · hours
PK: t(1/2)
hoursParent Drug KD025Metabolite M2
t(1/2): Day 16.08 ± 0.6814.25 ± 3.95
t(1/2): Day 285.27 ± 0.6922.26 ± NA

Adverse events

Collected over 12 weeks: up to 4 weeks for screening, 4 weeks of treatment, and 4 weeks of follow-up.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belumosudil 200 mg PO QD0/8 (0%)1/8 (12.5%)4/8 (50%)
Most frequent serious events
Most frequent serious events
EventBelumosudil 200 mg PO QD
NauseaGastrointestinal disorders1/8
VomitingGastrointestinal disorders1/8
Anastomotic ulcerInjury, poisoning and procedural complications1/8
NephrolithiasisRenal and urinary disorders1/8
Most frequent other events
Showing 10 of 11
Most frequent other events
EventBelumosudil 200 mg PO QD
Transaminase increasedInvestigations2/8
NauseaGastrointestinal disorders1/8
VomitingGastrointestinal disorders1/8
Anastomotic ulderInjury, poisoning and procedural complications1/8
NephrolithiasisRenal and urinary disorders1/8
PyrexiaGeneral disorders1/8
HypokalemiaMetabolism and nutrition disorders1/8
Rib FractureInjury, poisoning and procedural complications1/8
FallInjury, poisoning and procedural complications1/8
SomnolenceNervous system disorders1/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)Belumosudil 200 mg PO QD
Mean47.6 ± 10.31
Age, Customized
Age, Customized(years)Belumosudil 200 mg PO QD
Median49.5 (31 to 57)
Sex: Female, Male
Sex: Female, Male(Participants)Belumosudil 200 mg PO QD
Female0
Male8
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Belumosudil 200 mg PO QD
BMI
BMI(kg/m^2)Belumosudil 200 mg PO QD
Mean29.42 ± 6.539
BMI
BMI(kg/m^2)Belumosudil 200 mg PO QD
Median27.61 (21.2 to 41.0)
08

Study locations

1 site
  • UC Irvine Health, Dept of Dermatology
    Irvine, California 92697, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2021, 7 years after primary completion. A results delay was requested in Oct 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2014
First posted
Apr 8, 2014
Start
Apr 2014
Primary completionActual
Sep 2014
CompletionActual
Sep 2014
Results delay requested
Oct 9, 2014
Results first posted
Sep 13, 2021
Last update
Mar 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02106195
Responsible party
Sponsor
First posted
Apr 8, 2014
Start date
Apr 2014
Primary completion
Sep 2014
Completion
Sep 2014
Results posted
Sep 13, 2021
Last update
Mar 23, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belumosudil

Start the discussion